Cargando…
A Prospective Open‐Label Observational Study of a Buffered Soluble 70 mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The GastroPASS Study
Upper gastrointestinal (GI) side effects are a main reason for discontinuing bisphosphonate treatment, an important therapeutic option for osteoporosis patients. Consequently, the development of novel formulations with improved tolerability is warranted. In this multicenter prospective, observationa...
Autores principales: | Minisola, Salvatore, Vargas, Antonio P, Letizia Mauro, Giulia, Bonet Madurga, Fernando, Adami, Giovanni, Black, Dennis M, Qizilbash, Nawab, Blanch‐Rubió, Josep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260812/ https://www.ncbi.nlm.nih.gov/pubmed/34258506 http://dx.doi.org/10.1002/jbm4.10510 |
Ejemplares similares
-
Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
por: Hiligsmann, M., et al.
Publicado: (2021) -
The Effect of Effervescent and Buffered Alendronate Compared to Conventional Alendronate on Markers of Bone Turnover: A Randomized Non-inferiority Trial
por: Hikmet, Rawan, et al.
Publicado: (2023) -
Cost–effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
por: Casado, Enrique, et al.
Publicado: (2023) -
Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation
por: Bone, H. G., et al.
Publicado: (2017) -
Formulation and Characterization of an Effervescent Hydrogen-Generating Tablet
por: Rosch, Moritz, et al.
Publicado: (2021)